Axa S.A. Chimerix Inc Transaction History

Axa S.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.34 - $5.34 $261,568 - $1.04 Million	-195,200 Closed	0 $0
Q1 2022 Feb 14, 2023	BUY	$4.58 - $6.8 $894,016 - $1.33 Million	195,200 New	195,200 $894,000
Q4 2021 Feb 14, 2022	SELL	$5.23 - $7.18 $60,145 - $82,570	-11,500 Reduced 5.56%	195,200 $1.26 Million
Q3 2021 Nov 15, 2021	BUY	$5.94 - $8.75 $991,386 - $1.46 Million	166,900 Added 419.35%	206,700 $1.28 Million
Q1 2021 May 14, 2021	BUY	$4.76 - $11.25 $70,924 - $167,625	14,900 Added 59.84%	39,800 $384,000
Q4 2020 Feb 12, 2021	BUY	$2.43 - $5.42 $60,507 - $134,958	24,900 New	24,900 $120,000
Q4 2019 Feb 18, 2020	SELL	$1.3 - $2.72 $268,190 - $561,136	-206,300 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$2.05 - $4.32 $119,049 - $250,875	-58,073 Reduced 21.97%	206,300 $891,000
Q1 2019 May 14, 2019	SELL	$1.79 - $3.12 $97,913 - $170,664	-54,700 Reduced 17.14%	264,373 $555,000
Q4 2017 Feb 13, 2018	BUY	$4.32 - $5.52 $226,368 - $289,248	52,400 Added 19.65%	319,073 $1.48 Million
Q3 2017 Nov 13, 2017	BUY	$4.35 - $5.25 $1.16 Million - $1.4 Million	266,673	266,673 $1.4 Million

37.2M

52.7K

130K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $400M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.